Venetoclax for chronic lymphocytic leukemia in real-world care
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at how well venetoclax works and how it’s used when people with chronic lymphocytic leukemia (CLL) start the medication in usual, real-life care. It may help doctors better understand what to expect outside of strict study settings.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have chronic lymphocytic leukemia (CLL)
- You are starting venetoclax therapy (or have just started)
- Your venetoclax treatment follows the approved instructions in your local label
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether adding oral venetoclax together with an IV antibody called obinutuzumab can control CLL when the disease comes back after a specific prior treatment. It also looks closely at side effects to see what changes in “disease activity” and safety to expect.
This Phase 2 trial tests a combination of three medicines to treat chronic lymphocytic leukemia (CLL) that has not been treated before and where the goal is to achieve very low remaining disease. It may help some people stay in remission longer, but eligibility depends on your age, organ function, and prior treatments.
This study looks at the long-term safety and how well treatment is working in people with CLL who received a combination of ibrutinib plus venetoclax. By following participants over time, researchers hope to learn more about the lasting effects and benefits of this treatment approach.
This trial tests how well venetoclax (a targeted pill for CLL) works in people whose CLL has come back or hasn’t responded. It also closely tracks early changes in the CLL cells to better understand what happens during treatment.
This study looks at why chronic lymphocytic leukemia may stop responding after a medicine called venetoclax. By analyzing tumor samples, researchers hope to better understand resistance and guide future treatment options.
This study looks at how the environment inside lymph nodes changes in people with chronic lymphocytic leukemia (CLL) who are being treated with venetoclax. It may help doctors better understand what’s happening in the body during treatment and improve future care.
Hear when a new Chronic Lymphocytic Leukemia (CLL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.